Evidence map›Paper›PMID 36694810›Full record

ArticleIJID regions2023

Estimation of real COVID-19 cases in India during the first wave.

Prajjval Pratap Singh, Sunil Kumar Rai, Gyaneshwer Chaubey, Serosurveillance Consortium BHU

Abstract read
In one paragraph

Article in IJID regions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Authors' response.The Indian journal of medical research · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Prajjval Pratap SinghCytogenetics Laboratory, Department of Zoology, Banaras Hindu University, Varanasi, India.
Sunil Kumar RaiCytogenetics Laboratory, Department of Zoology, Banaras Hindu University, Varanasi, India.
Gyaneshwer ChaubeyCytogenetics Laboratory, Department of Zoology, Banaras Hindu University, Varanasi, India.
Serosurveillance Consortium BHU

Funding

Wellcome Trust
6 · The paper itself

Abstract

In 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread across the world within a few months. The SARS-CoV-2 pandemic has had a devastating effect on humanity, with social and economic consequences. The continents of Europe and America have been hit the hardest. However, there has also been a huge loss of life in India, with the country having the fourth highest number of total deaths worldwide. Nevertheless, the infection and death rates per million and the case fatality ratio in India are substantially lower than those in many developed nations. Several explanations for this have been proposed, including genetics. Mathematical modelling has suggested that the actual number of infections is much higher than the number of reported cases. Therefore, to understand the dynamics of actual infection and the population-level immunity against SARS-CoV-2, a serosurvey (antibody testing) was performed among 2301 individuals in urban regions of 14 districts in six states of India. A notable outcome of this study was that a large proportion of the Indian population had an asymptomatic SARS-CoV-2 infection. The real infection rate in India was several fold higher than the reported number of cases. Therefore, a large number of people in the country have developed SARS-CoV-2-specific antibodies. In this survey, the seroprevalence (frequency antibody-positive) varied between 0.01 (95% CI 0.002-0.054) and 0.477 (95% CI 0.392-0.563), suggesting a high variability in viral transmission between the states and the possibility of future waves. In this study population, the frequency of asymptomatic infection was highest in the younger age groups. It was also found that the numbers of cases reported by the government were several-fold lower than the real incidence of infection. It is likely that the high number of asymptomatic cases was the main driver of this discrepancy.

Indexed as

AntibodyCoronavirusIndiaSARS-CoV-2Seroprevalence

Identifiers

PMID36694810
PMCPMC9851738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.